 Darin Jones
Concepts (106)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Enzyme Inhibitors | 4 | 2021 | 374 | 0.500 |
Why?
| | Glycoside Hydrolases | 2 | 2021 | 21 | 0.350 |
Why?
| | Small Molecule Libraries | 2 | 2021 | 67 | 0.330 |
Why?
| | Asteraceae | 2 | 2022 | 9 | 0.320 |
Why?
| | Lactones | 2 | 2020 | 26 | 0.300 |
Why?
| | Sesquiterpenes | 2 | 2020 | 88 | 0.280 |
Why?
| | DNA Repair | 2 | 2021 | 188 | 0.210 |
Why?
| | Leukocytes, Mononuclear | 2 | 2020 | 119 | 0.200 |
Why?
| | Nucleic Acids | 1 | 2021 | 13 | 0.190 |
Why?
| | Severe Acute Respiratory Syndrome | 1 | 2021 | 17 | 0.190 |
Why?
| | DNA Replication | 2 | 2019 | 156 | 0.180 |
Why?
| | Leukemia, Myeloid, Acute | 2 | 2020 | 181 | 0.180 |
Why?
| | Uracil-DNA Glycosidase | 1 | 2021 | 7 | 0.180 |
Why?
| | Xanthines | 1 | 2021 | 8 | 0.180 |
Why?
| | Antiviral Agents | 1 | 2021 | 171 | 0.160 |
Why?
| | Structure-Activity Relationship | 6 | 2021 | 395 | 0.150 |
Why?
| | Pyridazines | 1 | 2017 | 11 | 0.140 |
Why?
| | Antineoplastic Agents | 2 | 2016 | 1173 | 0.140 |
Why?
| | Cell Proliferation | 1 | 2020 | 986 | 0.130 |
Why?
| | Benzamidines | 1 | 2015 | 5 | 0.120 |
Why?
| | Catalytic Domain | 3 | 2021 | 57 | 0.120 |
Why?
| | Protease Inhibitors | 1 | 2015 | 58 | 0.120 |
Why?
| | Serine Endopeptidases | 1 | 2015 | 51 | 0.120 |
Why?
| | Crystallography, X-Ray | 4 | 2021 | 145 | 0.110 |
Why?
| | Factor VIIa | 2 | 2003 | 9 | 0.110 |
Why?
| | Intramolecular Oxidoreductases | 1 | 2012 | 12 | 0.100 |
Why?
| | Neoplasm Proteins | 1 | 2015 | 321 | 0.100 |
Why?
| | Pyrazines | 2 | 2003 | 187 | 0.100 |
Why?
| | Fibrinolytic Agents | 2 | 2003 | 125 | 0.100 |
Why?
| | Anti-Inflammatory Agents | 1 | 2012 | 167 | 0.090 |
Why?
| | Neoplasms | 1 | 2019 | 1250 | 0.080 |
Why?
| | Molecular Docking Simulation | 2 | 2021 | 73 | 0.080 |
Why?
| | Inflammation | 1 | 2012 | 610 | 0.070 |
Why?
| | Kinetics | 3 | 2017 | 634 | 0.070 |
Why?
| | Drug Discovery | 2 | 2021 | 85 | 0.070 |
Why?
| | Models, Molecular | 3 | 2021 | 334 | 0.070 |
Why?
| | Cell Line, Tumor | 2 | 2020 | 1403 | 0.060 |
Why?
| | Humans | 11 | 2021 | 50673 | 0.060 |
Why?
| | Thromboplastin | 1 | 2003 | 4 | 0.050 |
Why?
| | Drug Design | 3 | 2015 | 119 | 0.050 |
Why?
| | Chromatography, Thin Layer | 1 | 2022 | 24 | 0.050 |
Why?
| | Amino Acid Sequence | 2 | 2021 | 578 | 0.050 |
Why?
| | Plants | 1 | 2022 | 26 | 0.050 |
Why?
| | Uracil | 1 | 2021 | 6 | 0.050 |
Why?
| | Minor Histocompatibility Antigens | 1 | 2021 | 17 | 0.050 |
Why?
| | Cytidine Deaminase | 1 | 2021 | 12 | 0.050 |
Why?
| | Tyramine | 1 | 2020 | 5 | 0.040 |
Why?
| | NF-kappa B p50 Subunit | 1 | 2020 | 16 | 0.040 |
Why?
| | Gene Expression Regulation, Leukemic | 1 | 2020 | 29 | 0.040 |
Why?
| | Heme Oxygenase-1 | 1 | 2020 | 18 | 0.040 |
Why?
| | HSP70 Heat-Shock Proteins | 1 | 2020 | 60 | 0.040 |
Why?
| | Morpholines | 1 | 2020 | 66 | 0.040 |
Why?
| | Plant Extracts | 1 | 2022 | 175 | 0.040 |
Why?
| | Poly(ADP-ribose) Polymerases | 1 | 2019 | 29 | 0.040 |
Why?
| | Piperidines | 1 | 2020 | 99 | 0.040 |
Why?
| | DNA Damage | 1 | 2021 | 300 | 0.040 |
Why?
| | Cell Death | 1 | 2019 | 175 | 0.040 |
Why?
| | Recombinant Proteins | 2 | 2015 | 479 | 0.040 |
Why?
| | Genes, Plant | 1 | 1997 | 9 | 0.040 |
Why?
| | alpha-Galactosidase | 1 | 1997 | 9 | 0.040 |
Why?
| | Fabaceae | 1 | 1997 | 6 | 0.040 |
Why?
| | ABO Blood-Group System | 1 | 1997 | 15 | 0.040 |
Why?
| | Plants, Medicinal | 1 | 1997 | 35 | 0.030 |
Why?
| | Plant Proteins | 1 | 1997 | 68 | 0.030 |
Why?
| | Isoenzymes | 1 | 1997 | 166 | 0.030 |
Why?
| | Ecuador | 1 | 2016 | 4 | 0.030 |
Why?
| | HL-60 Cells | 1 | 2016 | 18 | 0.030 |
Why?
| | Medicine, Traditional | 1 | 2016 | 19 | 0.030 |
Why?
| | Drug Screening Assays, Antitumor | 1 | 2016 | 132 | 0.030 |
Why?
| | HeLa Cells | 1 | 2016 | 257 | 0.030 |
Why?
| | Peptidomimetics | 1 | 2015 | 2 | 0.030 |
Why?
| | Amidines | 1 | 2015 | 8 | 0.030 |
Why?
| | Molecular Structure | 1 | 2016 | 296 | 0.030 |
Why?
| | Enzyme Assays | 1 | 2015 | 9 | 0.030 |
Why?
| | Guanidines | 1 | 2015 | 29 | 0.030 |
Why?
| | High-Throughput Screening Assays | 1 | 2015 | 35 | 0.030 |
Why?
| | Urea | 1 | 2015 | 80 | 0.030 |
Why?
| | Blotting, Western | 1 | 2016 | 577 | 0.030 |
Why?
| | Phenylalanine | 1 | 2015 | 134 | 0.030 |
Why?
| | Piperazines | 1 | 2015 | 120 | 0.030 |
Why?
| | Thrombin | 2 | 2003 | 36 | 0.030 |
Why?
| | Arginine | 1 | 2015 | 187 | 0.030 |
Why?
| | Combinatorial Chemistry Techniques | 1 | 2003 | 9 | 0.010 |
Why?
| | Serine Proteinase Inhibitors | 1 | 2003 | 10 | 0.010 |
Why?
| | Antithrombin III | 1 | 2003 | 12 | 0.010 |
Why?
| | Trypsin Inhibitors | 1 | 2003 | 1 | 0.010 |
Why?
| | Prothrombin | 1 | 2003 | 4 | 0.010 |
Why?
| | Peptide Library | 1 | 2003 | 16 | 0.010 |
Why?
| | Inhibitory Concentration 50 | 1 | 2003 | 68 | 0.010 |
Why?
| | Indicators and Reagents | 1 | 2003 | 38 | 0.010 |
Why?
| | Molecular Conformation | 1 | 2003 | 66 | 0.010 |
Why?
| | Thiazoles | 1 | 2003 | 54 | 0.010 |
Why?
| | Binding Sites | 1 | 2003 | 365 | 0.010 |
Why?
| | Thrombosis | 1 | 2003 | 250 | 0.010 |
Why?
| | DNA, Plant | 1 | 1997 | 4 | 0.010 |
Why?
| | Consensus Sequence | 1 | 1997 | 24 | 0.010 |
Why?
| | Molecular Weight | 1 | 1997 | 83 | 0.010 |
Why?
| | Sequence Alignment | 1 | 1997 | 119 | 0.010 |
Why?
| | DNA, Complementary | 1 | 1997 | 134 | 0.010 |
Why?
| | Sequence Homology, Amino Acid | 1 | 1997 | 144 | 0.010 |
Why?
| | Cloning, Molecular | 1 | 1997 | 191 | 0.010 |
Why?
| | Substrate Specificity | 1 | 1997 | 190 | 0.010 |
Why?
| | Recombinant Fusion Proteins | 1 | 1997 | 186 | 0.010 |
Why?
| | Base Sequence | 1 | 1997 | 644 | 0.010 |
Why?
| | Escherichia coli | 1 | 1997 | 191 | 0.010 |
Why?
| | Molecular Sequence Data | 1 | 1997 | 782 | 0.010 |
Why?
|
|
Jones's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|